Citation Impact
Citing Papers
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
2008 Standout
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
2013 StandoutScienceNobel
Fibroblast growth factor receptor 3-IIIc mediates colorectal cancer growth and migration
2010
Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice
2009
Chronic myeloproliferative diseases with and without the Ph chromosome: some unresolved issues
2009
The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies
2012
The FGF family: biology, pathophysiology and therapy
2009 Standout
Oncogene addiction: setting the stage for molecularly targeted cancer therapy
2007
Advances and challenges in targeting FGFR signalling in cancer
2017
Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders
2007
Regulation of chromatin by histone modifications
2011 Standout
A positive FGFR3/FOXN1 feedback loop underlies benign skin keratosis versus squamous cell carcinoma formation in humans
2009
Cancer Epigenetics: From Mechanism to Therapy
2012 Standout
Pathogenesis of myeloma bone disease
2008
Targeting cancer with small molecule kinase inhibitors
2008 Standout
Natural products to drugs: natural product-derived compounds in clinical trials
2008 Standout
Fibroblast growth factor signalling: from development to cancer
2010 Standout
Ba/F3 cells and their use in kinase drug discovery
2006
Vaccine adjuvants – understanding molecular mechanisms to improve vaccines
2014 StandoutNobel
Genetic events in the pathogenesis of multiple myeloma
2007
Sixteen years and counting: The current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias
2011
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
2007
The cancer stem cell: premises, promises and challenges
2011 Standout
Recent advances in bone tissue engineering scaffolds
2012 Standout
CASK Functions as a Mg2+-Independent Neurexin Kinase
2008 StandoutNobel
Deficient CCR7 signaling promotes TH2 polarization and B‐cell activation in vivo
2011
Basic and Therapeutic Aspects of Angiogenesis
2011 Standout
Molecular mechanisms and clinical applications of angiogenesis
2011 StandoutNature
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
2020 Standout
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
The Fibroblast Growth Factor signaling pathway
2015 Standout
Etiology and management of tumor lysis syndrome in patients with chronic lymphocytic leukemia.
2009
FGF Receptors: Cancer Biology and Therapeutics
2013
The Tumor Lysis Syndrome
2011 Standout
Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma
2007
Individualizing Treatment of Patients With Myeloma in the Era of Novel Agents
2008
Multiple Myeloma
2010
Antitumor activity of fibroblast growth factor receptor 3–specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis
2008
Cancer Genome Landscapes
2013 StandoutScience
The Bcl-2 Family Protein Inhibitor, ABT-737, Has Substantial Antimyeloma Activity and Shows Synergistic Effect with Dexamethasone and Melphalan
2007
Multiple Myeloma
2011 Standout
AZD2171 Shows Potent Antitumor Activity Against Gastric Cancer Over-Expressing Fibroblast Growth Factor Receptor 2/Keratinocyte Growth Factor Receptor
2007
Fibroblast Growth Factor Receptor 1 Promotes Proliferation and Survival via Activation of the Mitogen-Activated Protein Kinase Pathway in Bladder Cancer
2009
Works of Ellen Wei being referenced
The SH3–SAM Adaptor HACS1 is Up-regulated in B Cell Activation Signaling Cascades
2004
A Phase II Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL)
2008
CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma
2004
MIP-1α (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma
2006
The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells
2006
A Phase II Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL).
2007